BBCMF (Lir Life Sciences) Liabilities-to-Assets : 0.07 (As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BBCMF Lir Life Sciences Corp BBCMF
15 GF Score
Price $0.05
View Full Analysis

What is Lir Life Sciences Liabilities-to-Assets?

Lir Life Sciences BBCMF 15 Liabilities-to-Assets is 0.07 as of Jan. 2026. GuruFocus rates BBCMF with a GF Score™ of 15/100.

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Lir Life Sciences's Total Liabilities for the quarter that ended in Jan. 2026 was $0.06 Mil. Lir Life Sciences's Total Assets for the quarter that ended in Jan. 2026 was $0.83 Mil. Therefore, Lir Life Sciences's Liabilities-to-Assets Ratio for the quarter that ended in Jan. 2026 was 0.07.

Lir Life Sciences  (OTCPK:BBCMF) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Lir Life Sciences Liabilities-to-Assets Related Terms

Lir Life Sciences Liabilities-to-Assets Historical Data

* Premium members only.

The historical data trend for Lir Life Sciences's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lir Life Sciences Liabilities-to-Assets Chart

Lir Life Sciences Annual Data
Trend Apr24 Apr25
Liabilities-to-Assets
1.13 1.67

Lir Life Sciences Quarterly Data
Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Liabilities-to-Assets Get a 7-Day Free Trial 0.00 1.67 3.44 0.04 0.07

BBCMF vs VRTX, REGN, ALNY: Liabilities-to-Assets Comparison

For the Biotechnology subindustry, Lir Life Sciences's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lir Life Sciences Liabilities-to-Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lir Life Sciences's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Lir Life Sciences's Liabilities-to-Assets falls into.


BBCMF
15GF Score
Lir Life Sciences Corp BBCMF
Liabilities-to-Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lir Life Sciences Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Lir Life Sciences's Liabilities-to-Assets Ratio for the fiscal year that ended in Apr. 2025 is calculated as:

Liabilities-to-Assets (A: Apr. 2025 )=Total Liabilities/Total Assets
=0.145/0.087
=1.67

Lir Life Sciences's Liabilities-to-Assets Ratio for the quarter that ended in Jan. 2026 is calculated as

Liabilities-to-Assets (Q: Jan. 2026 )=Total Liabilities/Total Assets
=0.057/0.829
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Liabilities-to-Assets →
What does a Liabilities-to-Assets of 0.07 mean?
Lir Life Sciences (BBCMF) has a Liabilities-to-Assets of 0.07 as of Jan. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Lir Life Sciences and its competitors.
Is Lir Life Sciences' Liabilities-to-Assets too high?
Lir Life Sciences' current Liabilities-to-Assets is 0.07. Overall, Lir Life Sciences has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Lir Life Sciences' Liabilities-to-Assets compare to VRTX and REGN?
Lir Life Sciences' Liabilities-to-Assets of 0.07 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Biotechnology company?
A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Lir Life Sciences and its competitors. Lir Life Sciences's current Liabilities-to-Assets is 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lir Life Sciences stock overvalued right now?
Lir Life Sciences (BBCMF) has a current Liabilities-to-Assets of 0.07. The current Liabilities-to-Assets is 0.07. Lir Life Sciences' overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Lir Life Sciences (BBCMF), the current Liabilities-to-Assets is 0.07 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lir Life Sciences Business Description

Other Exchanges N790:GermanySKNY:Canada
Address 505-1505 West 2nd Avenue, Vancouver, BC, CAN, V6J 1H2
Lir Life Sciences Corp is a biotechnology company developing transdermal and sublingual drug-delivery technologies for GLP-1-based obesity therapies, with the focus of improving accessibility and patient experience.
15GF Score

Get the complete analysis for BBCMF

Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.05
Price